Considering the specificity of RTX for CD20, the impact of the BLNK and BTK genes on RTX resistance suggests that stimulation of CD20 feeds into BCR signaling, a claim which is also supported by recent publications linking RTX response in chronic lymphocytic leukemia to BCR signal‐proficient cell populations [54] and studies of RTX‐induced BCR signaling in follicular lymphoma cell lines [21]. This evidence concerns the gene BCR and follicular lymphoma.